Doubling the THC Doesn't Double the High. So Why Is Everyone Selling It That Way?

If you have ever stood at a dispensary counter holding two jars that look the same, one labeled 10 mg a serving and one labeled 20, you already know the pull. The bigger number feels like the better deal. Every purchase you have ever made has taught you that more of the thing is more of the thing.

A pooled analysis of 41 experiments, newly published in Neuroscience & Biobehavioral Reviews, says that instinct is mostly wrong here.

The industry sells potency as a straight line. Your brain runs it as a plateau.

That is the finding, and it is worth slowing down on, because it cuts against how legal cannabis is priced, marketed, and, increasingly, regulated.

Forty-one experiments, one flattening curve

A meta-analysis is what researchers do when single experiments are too small to trust on their own: gather every comparable study, line up the numbers, and see what the whole pile says. Isabella Goodwin of Australian Catholic University and Amir Englund of King’s College London pooled 41 placebo-controlled studies covering 1,020 people who used cannabis less than once a week. They converted every dose to a single yardstick, a “Standard THC Unit” of 5 mg inhaled, and subtracted whatever people reported feeling on placebo, per their own write-up in The Conversation.

One standard unit raised self-rated “high” by 34 points on a 100-point scale. It also raised anxiety by 14 points and tiredness by 26, and it pushed alertness down by 40. Then the authors asked the question the counter never answers: what does a second unit buy? Going from 5 mg to 10 mg moved the “high” score from 34 to 39, roughly 15 percent more. Anxiety, tiredness, and alertness did not measurably change. “The high rises quickly at low doses, but extra THC soon adds less and less,” Goodwin and Englund write.

Put plainly: the first few milligrams do most of the work. The rest is mostly paying for milligrams.

What the plateau can’t tell you

A finding this tidy deserves its limits, and a reader who has been sold to before will want them. The people in these studies used cannabis rarely, so they had little tolerance, which is the brain’s habit of turning down its own response when it is hit often. The doses were inhaled, so the numbers say nothing about edibles, which arrive late and make it easy to take more before the first dose lands. The outcomes were self-reported feelings in a lab, not driving, not work, not sleep, and not the weeks after. And a meta-analysis can only be as good as the 41 studies inside it.

So the plateau is not a promise that more is harmless. It says that for a low-tolerance person, a bigger dose mostly isn’t buying a bigger effect. It does not say what happens to someone who uses every day, or someone whose use has stopped being a choice. That is the unfinished half of this science, and anyone who tells you the plateau settles it is selling something.

What you can do with it is ask a different question. If the extra milligrams are not buying the effect, what are they buying? For some people the answer is tolerance, which is the brain sliding the target further away. The authors’ own advice, “start low, go slow,” is the same finding turned into a sentence.

The law just started calling the jar medicine

On Friday, October 30, Attorney General Todd Blanche announced that the DEA had issued federal registrations to more than 900 medical marijuana dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia, and West Virginia, which the Justice Department called the “first phase” of implementing rescheduling. “The American people deserve access to the best medical treatments in the world,” Blanche said. The department’s own release is clear about the gate: state licensure alone does not grant federal registration, and registered dispensaries take on federal security and recordkeeping requirements.

The department’s own release is clear about the gate: state licensure alone does not grant federal registration, and registered dispensaries take on federal security and recordkeeping requirements.

That gate matters before anyone calls this a change on the ground. It covers products sold under a state medical license, in the states above, to the businesses that applied and were approved. It is not adult-use legalization, and it is not a clinical standard of care.

We have watched this contradiction harden before. In 1996, California voters passed Proposition 215 and became the first state to let patients use cannabis on a doctor’s recommendation. Washington answered by keeping the plant in Schedule I. In 2005, in Gonzales v. Raich, the Supreme Court ruled that Congress could still prohibit even home-grown medical cannabis that never crossed a state line. For two decades after, a patient could be legal in her state, a criminal in her country, and invisible to the clinicians who might have helped her figure out how much was enough. Registering dispensaries in October 2026 is the first time the DEA has registered state-licensed medical dispensaries under the new order. It put a federal name on the shelf. It did not put a clinician beside the person.

Who actually tells people how much

Here is the part the law skips. A federally funded survey of 1,023 adults who had used THC in the past month, published in 2026 in Drugs: Education, Prevention and Policy, asked whom they trust for cannabis information. Dispensary staff scored highest, 3.7 on a five-point scale, ahead of friends (3.5), healthcare providers (3.4), government officials (2.9), and social media (2.6). Among people who use for fun or relaxation, 47 percent named dispensary staff first. Four percent named a healthcare provider.

The plateau finding has to reach someone, and today that someone is the person behind the counter, not the clinic. Whether that person has ever read Goodwin and Englund is not something the survey can tell us.

What to do with a plateau

For providers, one concrete move this week: add a single question to intake or follow-up. Not “how much do you use?”, which gets the defended answer, but “What are you getting from the last third of what you use?” If the honest answer is “not much,” you have motivation you did not have to manufacture. If the answer is “I need it just to feel normal,” you have learned something more important, and you can screen for cannabis use disorder with the tools your program already uses.

For anyone reading this who is working on cutting back or on stopping, the plateau is a small piece of footing: the extra isn’t doing what the label implies, and you are allowed to notice that.

The person at the counter on Tuesday will make a choice about two jars. A better answer than “the bigger one” exists now. Whether anyone says it out loud to them is the open question, and it is a question about people, not chemistry.